Anthropic priced its IPO at $83. Before listing, it had already bought a one-person drug developer.

01 · One founder, eleven labs

Claude's developer began trading on Nasdaq as ANT on November 19. [3] The final price exceeded the preliminary range of $70 to $78. [1][2]

Twelve-month revenue through September came to $35.3 billion, calculated from the prospectus. [1]

That figure covers the whole company. [1][2][3]

Nasdaq's Economic Institute put the valuation at about $1.5 trillion at the offer price. [14]

Anthropic disclosed its acquisition of Mithril Medicine on October 27, alongside six projects with drug developers and investors. [4]

The purchase price was undisclosed. The projects show where Claude can make itself useful even when a medicine is years away from a trial. [4]

Figure 1|Four points of entry for AI

From candidate design to trial planning, each step produces a different piece of evidence.

Mithril founder Cody Tranbarger used Claude to coordinate work with 11 outside labs. [4]

11 · outside labs

One muscular dystrophy program went from an idea to mouse data in under 18 months. [4] Mithril is working on two rare forms of muscular dystrophy. [4]

The team still has to choose a candidate and clear the work required for human testing.

Anthropic gave late 2028 as the earliest possible start for one trial, conditional on the work holding up. [4]

That date sets a clock for the project. [4]

In our November 1 Chinese-language analysis, the business question was who would take the drugs forward.

The IPO brings a new audience to the same question. The six cases help put a price on specific work.

02 · What the partners could measure

Generate Biomedicines worked on a component of an experimental CAR-T approach for solid tumors.

One CAR-T component was about 70% shorter than the standard version. [4] The team also reported lab improvements.

70% · shorter than the standard version

Patient safety and clinical efficacy remain open. [4]

Divergence Labs used Claude to generate about 35,000 antibody designs in roughly a month for a food allergy project. [4]

Some scored as hits in early testing. The team still needs to bring its early findings together in a single candidate. [4]

Figure 2|Six partners and their assignments

One case counts designs, another measures time, and another evaluates trial plans.

BigHat Biosciences went further into the lab.

It built and tested about 1,010 variants over roughly 10 weeks, with improvements on selected properties. [4]

The case offers experimental evidence for lead optimization. It leaves the clinical candidate and timeline open. [4]

Enveda used Claude to review 1,061 pages of manufacturing records. [4] Human review time fell by 89%. [4]

The company also tried Claude on regulatory drafts. It still had people review the work, and the case did not report shorter agency review. [4]

The Column Group was setting up Pleiades to see how much drug research a small team could take on.

It evaluated an early workflow on 45 target-disease pairs. [4] An evaluation of that size tells us the scope of the test.

45 · target-disease pairs

The public account gives no measured improvement in the rate of successful programs. [4]

Bristol Myers Squibb used Claude to evaluate options for an early clinical program.

A company executive said that an initial analysis would otherwise have taken days.

The case gave no standardized time saving or evidence of a higher likelihood of trial success. [4][5]

Taken together, the cases show how quickly a team can get to the next decision.

Evidence for that decision can be an assay result, a set of manufacturing records or a clinical plan.

Each still needs someone who can judge its quality.

03 · Who owns the next step

The same questions work across the business models. What task does the company own? How far has that specific program advanced?

What could an outsider check next?

Figure 3|Three ways into AI drug development

Some companies sell research capabilities. Others develop their own medicines or build tools around their own data.

Company and routeRolePublic progressNext checkpoint
Anthropic, model supplier [4]Rare disease research [4]Mouse data [4]Candidate selection [4]
Recursion, AI biotech [6]Develops REC-1245 [6]Early Phase 1 data [7]Expansion data [7]
Lilly, in-house pharma [8]Models using proprietary data [8]TuneLab launched [8]Evidence on a named asset [9]
Insilico, AI biotech [10]Develops rentosertib [10]First Phase 3 dose in China [10]Phase 3 lung function data [10]
XtalPi, discovery partner [12]Discovery. Pierre Fabre leads clinical development [12][13]Agreement announced [12]A named candidate [12]

Insilico's randomized Phase 2a study enrolled 71 people. [11] Narrowing a list of candidates was one hurdle. Insilico faces a different one now.

71 · people

It announced the first dose in a Chinese Phase 3 trial on September 10. [10]

A larger trial will show whether the earlier lung function signal holds up. [10][11] The XtalPi deal puts the commercial handoff earlier.

Under the agreement, XtalPi works on discovery and Pierre Fabre takes responsibility for clinical and commercial development.

A named candidate would give readers a stronger signal than another announcement about the platform. [12][13]

Lilly can approach the same work from inside pharma.

It already has the research data needed to build its own platform, and it gives other biotechs access through TuneLab.

Its joint lab with NVIDIA shows why general-purpose AI companies also face incumbent suppliers. [8][9]

04 · Two dates worth tracking

AI can make it cheaper to ask a question and quicker to close out an unpromising answer. The next expense is physical.

Drugmakers have to manufacture trial material, recruit participants and wait for the data.

Companies that control those decisions also carry the risk if the data disappoint.

Figure 4|The listing and Mithril's research timeline

The acquisition was already public before the IPO. The late-2028 trial window remains conditional.

The partnership test can arrive sooner.

Watch whether Enveda, BMS or the other partners put Claude to work on a second identifiable asset, and whether they are willing to say where it made a difference.

For Mithril, first dosing will be a clearer milestone than another set of mouse data.

By the end of 2027, a partner will disclose using Claude for clinical planning or filing on a second named asset, while Mithril will still be awaiting its first human dose.

This article is for industry analysis and does not constitute investment or medical advice.

References

  1. Final Prospectus · SEC EDGAR / Anthropic · 2026-11-18 · https://www.sec.gov/Archives/edgar/data/2130357/000162828026074944/anthropicpbc-424b4.htm
  2. Roadshow launch announcement · Anthropic · 2026-11-10 · https://www.anthropic.com/news/roadshow-launch
  3. Anthropic Marks its IPO · Nasdaq · 2026-11-19 · https://www.nasdaq.com/newsroom/anthropic-marks-ipo-at-nasdaq
  4. Early Progress on Accelerating Drug Development with Claude · Anthropic · 2026-10-27 · https://www.anthropic.com/research/early-progress-drug-development
  5. Strategic Agreement with Anthropic · Bristol Myers Squibb · 2026-05-20 · https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Strategic-Agreement-with-Anthropic-to-Position-Claude-Enterprise-as-the-Shared-Intelligence-Platform-Across-Its-Global-Operations/default.aspx
  6. First Quarter Update · Recursion · 2026-05-06 · https://ir.recursion.com/news-releases/news-release-details/recursion-reports-first-quarter-financial-results-and-provides
  7. Third Quarter Update · Recursion · 2026-11-02 · https://ir.recursion.com/news-releases/news-release-details/recursion-reports-third-quarter-2026-financial-results-and
  8. TuneLab Launch · Eli Lilly · 2025-09-09 · https://investor.lilly.com/news-releases/news-release-details/lilly-launches-tunelab-platform-give-biotechnology-companies
  9. Lilly and NVIDIA Co-Innovation Lab · Eli Lilly · 2026-01-12 · https://lilly.gcs-web.com/node/53651/pdf
  10. First Dose in GENESIS-IPF-3 · Insilico Medicine · 2026-09-10 · https://insilico.com/news/isn1009261-insilico-medicine-doses-first-patient-genesis-ipf-3
  11. Randomized Phase 2a Trial · Nature Medicine · 2025-06-03 · https://www.nature.com/articles/s41591-025-03743-2.pdf
  12. XtalPi Exchange Filing · XtalPi / HKEX · 2026-11-09 · https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1109/2026110900037.pdf
  13. Pierre Fabre and XtalPi Research Agreement · Pierre Fabre · 2026-11-09 · https://www.pierre-fabre.com/en/news/ai-drug-discovery
  14. IPO Valuation Context · Nasdaq Economic Institute · 2026-11-20 · https://www.nasdaq.com/economic-institute/chartstopper-112026
  15. Initial Public Offering Close · Anthropic · 2026-11-20 · https://www.anthropic.com/news/ipo-close

Share this analysis

Send this article to readers who follow biotech, company strategy, and capital-market signals.

Cite this article

For decks, research notes, or media references, cite Drugnews with the canonical article URL.

Drugnews Editorial Team. "Anthropic at $83 and Its Push Into Pharma." Drugnews, Nov 23, 2026. https://drugnews.com.tw/articles/2026-11-23-anthropic-ipo-ai-drug-development-en.html
This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.

Read this next

Continue with the most relevant Drugnews analysis on the same theme.

Nov 06, 2026Business Analysis

The Semiconductor Moment in AI Drug Discovery

How AI platforms and the discovery flywheel could open new partnership opportunities for AnHorn

AI
Nov 01, 2026Business Analysis

Anthropic's Drug Lab Will Sell to Pharma

Anthropic's S-1 shows $16.29bn in H1 2026 revenue and puts a wet lab, Coefficient Bio and in-house drug programs into its growth story. It is not running human trials, and nine of the top ten drugmakers are customers. Its likeliest path: license candidates to pharma.

AnthropicAI drug discoveryIPONovo NordiskCDMO
Jul 13, 2026Business AnalysisFree Article

Foundation Models Enter Drug Discovery: Anthropic Launches Claude Science as AI Companies Move Into the Real R&D Arena

Anthropic's launch of Claude Science and its move into drug discovery show foundation-model companies shifting from research tools into real R&D workflows. AI drug discovery will ultimately be judged by experiments, clinical data and tradable assets.

AI drug discoveryClaude ScienceAnthropicfoundation modelsdrug development